TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety, Tolerance and Metabolic Effects of Using a Preoperative Oral Nutritional Supplement (PreOP Booster) in Gastrointestinal Surgery
Brief Summary: The aim of this pilot study is to obtain data on the safety, tolerance and metabolic effects of the oral nutritional supplement (PreOP Booster) given to patients prior to gastrointestinal surgery.


Options:
A: Arm Label: Test; Type: EXPERIMENTAL; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: PreOP Booster (oral nutritional supplement, food for special medical purposes) | Intervention Type: DIETARY_SUPPLEMENT; Name: PreOP Booster (oral nutritional supplement, food for special medical purposes); Assigned to Arm(s): Control, Test
B: Arm Label: Aminolaban EN; Type: EXPERIMENTAL; Interventions: Drug: Aminoleban EN | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Drug: Aminoleban EN | Intervention Type: DRUG; Name: Aminoleban EN; Assigned to Arm(s): Aminolaban EN, Control
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Immunonutrition | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: food for special medical purposes (FSMP) | Intervention Type: DIETARY_SUPPLEMENT; Name: Immunonutrition; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: food for special medical purposes (FSMP); Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard ERAS group | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide), Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Intervention Type: DRUG; Name: Post operative laxation (Magnesium Oxide); Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Preoperative metabolic conditioning postoperative nutritional supplementation; Assigned to Arm(s): 3, 4 | Intervention Type: OTHER; Name: Standard ERAS group; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chemotherapy With or Without Preventive Anticoagulation for Metastatic Cancer of the Pancreas
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with chemotherapy. It is not yet known whether gemcitabine is more effective when given alone or together with dalteparin and/or capecitabine in treating patients with pancreatic cancer.

PURPOSE: This randomized phase III trial is studying whether dalteparin prevents blood clots in patients with pancreatic cancer receiving treatment with different combinations of gemcitabine and capecitabine.


Options:
A: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy at the investigator's discretion | Arm Label: dalteparin; Type: EXPERIMENTAL; Interventions: Drug: daltéparine, Drug: Chemotherapy at the investigator's discretion | Intervention Type: DRUG; Name: daltéparine; Assigned to Arm(s): dalteparin | Intervention Type: DRUG; Name: Chemotherapy at the investigator's discretion; Assigned to Arm(s): chemotherapy, dalteparin
B: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drug | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo drug; Assigned to Arm(s): Placebo drug
C: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
D: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chemotherapy With or Without Preventive Anticoagulation for Metastatic Cancer of the Pancreas
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Anticoagulants, such as dalteparin, may help prevent blood clots from forming in patients being treated with chemotherapy. It is not yet known whether gemcitabine is more effective when given alone or together with dalteparin and/or capecitabine in treating patients with pancreatic cancer.

PURPOSE: This randomized phase III trial is studying whether dalteparin prevents blood clots in patients with pancreatic cancer receiving treatment with different combinations of gemcitabine and capecitabine.


Options:
A: Arm Label: High TFMP: Enoxaparin; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: High TFMP: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low TFMP: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): High TFMP: Enoxaparin
B: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy at the investigator's discretion | Arm Label: dalteparin; Type: EXPERIMENTAL; Interventions: Drug: daltéparine, Drug: Chemotherapy at the investigator's discretion | Intervention Type: DRUG; Name: daltéparine; Assigned to Arm(s): dalteparin | Intervention Type: DRUG; Name: Chemotherapy at the investigator's discretion; Assigned to Arm(s): chemotherapy, dalteparin
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks | Intervention Type: DRUG; Name: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks; Assigned to Arm(s): A, B
D: Arm Label: A; Type: OTHER; Interventions: Drug: cisplatinum or carboplatin and e.g.etoposide. | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: cisplatinum or carboplatin and e.g.etoposide+enoxaparin | Intervention Type: DRUG; Name: cisplatinum or carboplatin and e.g.etoposide.; Assigned to Arm(s): A | Intervention Type: DRUG; Name: cisplatinum or carboplatin and e.g.etoposide+enoxaparin; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Randomised Prospective Comparative Multi-centre Intervention Study of Patients With Cystic Fibrosis and Early Diagnosed Diabetes Mellitus
Brief Summary: Is oral therapy with Repaglinide equivalent to insulin therapy with three daily injections with respect to blood glucose control, weight and pulmonary function over 2 years in patients with cystic fibrosis and secondary diabetes mellitus? That is the question examined in the phase III trial.


Options:
A: Arm Label: III; Type: PLACEBO_COMPARATOR; Interventions: Drug: Insulin Asparte, Drug: Repaglinide | Intervention Type: DRUG; Name: Insulin Asparte; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): III
B: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
C: Arm Label: Exercise; Type: OTHER; Interventions: Other: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Repaglinide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: short-acting Insulin (Actrapid) | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: short-acting Insulin (Actrapid); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Randomised Prospective Comparative Multi-centre Intervention Study of Patients With Cystic Fibrosis and Early Diagnosed Diabetes Mellitus
Brief Summary: Is oral therapy with Repaglinide equivalent to insulin therapy with three daily injections with respect to blood glucose control, weight and pulmonary function over 2 years in patients with cystic fibrosis and secondary diabetes mellitus? That is the question examined in the phase III trial.


Options:
A: Arm Label: III; Type: PLACEBO_COMPARATOR; Interventions: Drug: Insulin Asparte, Drug: Repaglinide | Intervention Type: DRUG; Name: Insulin Asparte; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): III
B: Arm Label: Telehealth; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Stress Management | Arm Label: Treatment-As-Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Stress Management; Assigned to Arm(s): Telehealth
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Repaglinide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: short-acting Insulin (Actrapid) | Intervention Type: DRUG; Name: Repaglinide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: short-acting Insulin (Actrapid); Assigned to Arm(s): 2
D: Arm Label: Growth Hormone Therapy; Type: EXPERIMENTAL; Interventions: Drug: Nutropin AQ | Intervention Type: DRUG; Name: Nutropin AQ; Assigned to Arm(s): Growth Hormone Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2/3 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control
Brief Summary: The purpose of this study is to determine whether dapagliflozin is effective in the treatment of type 2 diabetes in subjects with poor blood sugar control and moderate renal impairment


Options:
A: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300mg/Placebo | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300mg | Arm Label: 004; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300mg/Canagliflozin 150mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Canagliflozin 300mg/Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Canagliflozin 300mg/Canagliflozin 150mg; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Canagliflozin 300mg; Assigned to Arm(s): 003
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin, Drug: Metformin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Metformin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2
C: Arm Label: Intensified insulin treatment; Type: EXPERIMENTAL; Interventions: Drug: Intensified insulin treatment | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard treatment | Arm Label: Healthy controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Intensified insulin treatment; Assigned to Arm(s): Intensified insulin treatment | Intervention Type: DRUG; Name: Standard treatment; Assigned to Arm(s): Standard treatment
D: Arm Label: Dapagliflozin (10 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin | Arm Label: Dapagliflozin (5 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin (10 mg) | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin (5 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Multicenter, Placebo-controlled (standard Therapy + Placebo), Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients with Non-hypovolemic Non-acute Hyponatremia
Brief Summary: This is a randomized, double-blind, multicenter, placebo-controlled (standard therapy + placebo), phase 2 efficacy and safety study of the Tolvaptan tablets in treatment of patients with non-hypovolemic non-acute hyponatremia arising from a variety of etiologies. 240 (120 in each group) patients are to be enrolled randomly into Tolvaptan group or placebo group. Subjects in Tolvaptan group will receive standard therapy + Tolvaptan (15-60mg/day), while those in control group receiving standard therapy + placebo. The starting dose of tolvaptan is 15mg and it could be titrated up to 30mg and then,if necessary, to the maximum of 60mg according to a certain titration scheme based on patients' response of serum sodium level. The study includes a 2-day screening period from day -2 to day -1, 7-day inpatient study treatment (day 1 to day 7 ). After study treatment, subjects will be Followed-up on safety events on day 14 - 16. The Primary Efficacy Variable is the change of serum sodium from baseline. For patients with Congestive Heart Failure (CHF) or hepatic cirrhosis, change of body weight, fluid balance and symptoms improvement of CHF and hepatic edema will be assessed as secondary efficacy variables.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Conivaptan | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Conivaptan; Assigned to Arm(s): 1
B: Arm Label: Tolvaptan; Type: EXPERIMENTAL; Interventions: Drug: Tolvaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tolvaptan; Assigned to Arm(s): Tolvaptan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: tolvaptan; Assigned to Arm(s): N/A
D: Arm Label: Satavaptan; Type: EXPERIMENTAL; Interventions: Drug: Satavaptan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Satavaptan; Assigned to Arm(s): Satavaptan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addressing Parental Smoking by Changing Pediatric Office Systems
Brief Summary: RATIONALE: The Clinical Effort Against Secondhand Smoke (CEASE) program may be more effective than standard care in increasing the number of parents who stop smoking.

PURPOSE: This randomized clinical trial is studying how well the CEASE program works compared with standard care in helping parents stop smoking.


Options:
A: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: cancer prevention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: survey administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: study of high risk factors; Assigned to Arm(s): N/A
B: Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Brief intervention based in clinical practice guide | Intervention Type: BEHAVIORAL; Name: Brief intervention based in clinical practice guide; Assigned to Arm(s): Lifestyle counseling
C: Intervention Type: BEHAVIORAL; Name: SHS reduction intervention based on social cognitive learning theory; Assigned to Arm(s): N/A
D: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: School-based Care; Type: EXPERIMENTAL; Interventions: Behavioral: School-based Care | Intervention Type: BEHAVIORAL; Name: School-based Care; Assigned to Arm(s): School-based Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Addressing Parental Smoking by Changing Pediatric Office Systems
Brief Summary: RATIONALE: The Clinical Effort Against Secondhand Smoke (CEASE) program may be more effective than standard care in increasing the number of parents who stop smoking.

PURPOSE: This randomized clinical trial is studying how well the CEASE program works compared with standard care in helping parents stop smoking.


Options:
A: Arm Label: Assisted Referral & IVR; Type: EXPERIMENTAL; Interventions: Behavioral: Assisted referral & IVR | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assisted referral & IVR; Assigned to Arm(s): Assisted Referral & IVR
B: Intervention Type: BEHAVIORAL; Name: Advice; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Nicotine Gum and Patch; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): N/A
C: Arm Label: CBP + PF; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit and performance feedback (PF), Behavioral: Current Best Practices (CBP) | Arm Label: CBP + PF + P4P; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit and performance feedback (PF), Behavioral: Financial Incentive (P4P), Behavioral: Current Best Practices (CBP) | Arm Label: Current Best Practices (CBP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Current Best Practices (CBP) | Intervention Type: BEHAVIORAL; Name: Audit and performance feedback (PF); Assigned to Arm(s): CBP + PF, CBP + PF + P4P | Intervention Type: BEHAVIORAL; Name: Financial Incentive (P4P); Assigned to Arm(s): CBP + PF + P4P | Intervention Type: BEHAVIORAL; Name: Current Best Practices (CBP); Assigned to Arm(s): CBP + PF, CBP + PF + P4P, Current Best Practices (CBP)
D: Intervention Type: BEHAVIORAL; Name: smoking cessation intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: cancer prevention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: survey administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: study of high risk factors; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TBTC Study 30: A Phase I/II Pilot Study for Evaluation of Low Dose, Once Daily, Linezolid Plus Optimized Background Therapy (OBT) Versus Placebo Plus OBT for the Treatment of Multi-drug Resistant Tuberculosis
Brief Summary: The antibiotic linezolid when given for the treatment of multi-drug resistant tuberculosis is safe and tolerated at a low dose (600 mg daily) for a limited duration (16 weeks)


Options:
A: Arm Label: Delayed Start Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Delayed Start Linezolid | Arm Label: Immediate Start Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Immediate Start Linezolid | Intervention Type: DRUG; Name: Immediate Start Linezolid; Assigned to Arm(s): Immediate Start Linezolid | Intervention Type: DRUG; Name: Delayed Start Linezolid; Assigned to Arm(s): Delayed Start Linezolid
B: Arm Label: Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Linezolid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Moxifloxacin, Drug: Linezolid | Arm Label: Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Linezolid, Drug: Clofazimine | Arm Label: Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Linezolid | Arm Label: Control Regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB. | Intervention Type: DRUG; Name: Bedaquiline; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Pretomanid; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): Regimen 1 | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Clofazimine; Assigned to Arm(s): Regimen 2 | Intervention Type: DRUG; Name: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.; Assigned to Arm(s): Control Regimen
D: Arm Label: HIV infected; Type: EXPERIMENTAL; Interventions: Drug: INH, Rifampicin, Ethambutol and Pyrazinamide | Arm Label: HIV negative; Type: ACTIVE_COMPARATOR; Interventions: Drug: INH, Rifampicin, Ethambutol and Pyrazinamide | Intervention Type: DRUG; Name: INH, Rifampicin, Ethambutol and Pyrazinamide; Assigned to Arm(s): HIV infected | Intervention Type: DRUG; Name: INH, Rifampicin, Ethambutol and Pyrazinamide; Assigned to Arm(s): HIV negative

Answer: B